Genzyme has announced an update on Thyrogen availability. Due to unexpected delays in the release of three “lots” (or batches of Thyrogen) intended for both U.S. and global distribution, Genzyme now expects to stock-out of Thyrogen in the U.S. in late-July. Outside of the U.S., current stock-outs are expected to persist until these lots are released. In addition, temporary shipment delays and regional disparities in supply availability are expected to continue to occur for the remainder of 2011 and throughout 2012. This is due to a combination of factors, including: ongoing Thyrogen manufacturing capacity constraints; longer timelines to manufacture and release Thyrogen into the market; a lack of inventory of the product; and an increase in global demand for Thyrogen.
The American Thyroid Association recommends that health care providers not schedule patients for Thyrogen use unless its availability for that patient is confirmed. Selective use of Thyrogen during periods of product shortage may help preserve its availability for those who may benefit from it most.
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.